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Abstract
Despite expanded access to HIV treatment worldwide, poor HIV care outcomes persist among adolescent girls and young 
women (AGYW). This study was conducted among AGYW recruited from the HPTN 068 cohort who had sero-converted 
to HIV during the main trial between 2011 and 2014. The aim was to examine correlates of anti-retroviral treatment (ART) 
use. Log binomial regression was used to estimate the crude associations between social support, stigma, and HIV status 
disclosure and current ART use. Adjusted analyses were also conducted controlling for age and time since diagnosis. Seventy-
nine AGYW were included in this analysis. Median age of participants was 20 (range: 17 to 24) and time since diagnosis 
ranged from 0.5 to 4.8 years (median = 2.1). Over 75% of AGYW (n = 60) had sought HIV care at some point, with the same 
number reporting previous disclosure of their sero-status. However, just 43% (n = 34) of participants were on treatment at the 
time of the interview. Over half of participants (n = 44; 55.7%) reported social support was available to them most or all of 
the time, and the median stigma score was 90 (range 80–113). Adjusted analyses found higher current ART use among those 
who had disclosed their status (adjusted prevalence ratio (aPR): 3.19; 95% confidence interval (CI) 1.09, 9.32; p = 0.0339) 
and those with lower scores on the disclosure concern sub-scale of the Berger HIV Stigma Scale (aPR: 0.88; 95% CI 0.79, 
0.98; p = 0.0236). ART use among AGYW living with HIV and enrolled in HPTN 068 was low despite relatively high link-
age to care during the trial. Interventions aimed at minimizing individuals’ concerns about disclosure and improving onward 
disclosure of one’s status could further improve ART utilization among AGYW living with HIV in South Africa.
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Introduction
Adolescents continue to bear a disproportionate burden 
of the HIV epidemic worldwide. In South Africa specifi-
cally, over one-third of all new HIV infections occur among 
individuals ages 15 to 24 [1–3], with the majority of these 
infections occurring among young people ages 20 to 24 [4]. 
Evidence-based interventions aimed at improving access 
to HIV treatment among all people living with HIV, such 
as the adoption of the World Health Organization’s Uni-
versal Test and Treat policy in September 2016 [5], have 
been implemented nation-wide. However, improvements in 
HIV care outcomes among adolescents and young people 
continue to lag behind improvements seen in adult people 
living with HIV [3]. The most recent country estimates sug-
gest that while 63.1% of people ages 25–49 living with HIV 
are currently on anti-retroviral therapy (ART) just 39.9% 
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of young people ages 15 to 24 living with HIV are taking 
treatment [2, 6].
Though there is a dearth of empirical data regarding 
factors influencing linkage to and retention in care among 
adolescents and young people, as compared to adults [7], 
research has identified a number of factors which may con-
tribute to the disparities in HIV care outcomes described 
above. Adolescence is a time of physical and mental matu-
ration, as well as identity experimentation [8]. It is a period 
characterized by limited social support, lack of access to 
age-appropriate healthcare services, and increased vulner-
ability to stigma, discrimination, and poor mental health out-
comes [9–15]. Evidence suggests that these factors, as well 
as low proportions of HIV status disclosure, could contribute 
to poor HIV care outcomes among adolescents living with 
HIV (ALHIV) [9, 10, 14–21].
Given that the majority of South African ALHIV are not 
on treatment or virally suppressed [2, 3], there is a need to 
better understand factors associated with ART use in this 
highly vulnerable population. This study aims to character-
ize the association between: (1) social support, (2) HIV-
related stigma, and (3) status disclosure, and current ART 
use among a cohort of recently infected adolescent girls 
and young women (AGYW) living with HIV in rural South 
Africa. The goal of this work is to better inform interven-
tions to alleviate current treatment and care gaps in the area.
Methods
Study Design
This sub-study, henceforth referred to as “Engage”, is a 
cross-sectional study nested within the individually rand-
omized control trial HIV Prevention Trials Network (HPTN) 
068. Engage was conducted between 2011 and 2017 with
the primary aim of assessing the influence of key factors of
interest on HIV treatment and care uptake among AGYW
living with HIV.
Location
This study was conducted in the South African Medical 
Research Council and Wits University’s Agincourt Health 
and Socio-Demographic Surveillance System (HDSS) site 
in the Bushbuckridge sub-district of Mpumalanga province, 
South Africa [22]. The rural study site, with a population 
of roughly 115,000, is approximately 500 km northeast of 
Johannesburg and includes nine publicly funded healthcare 
facilities, which service a large proportion of the population 
[23, 24]. The site is characterized by high levels of HIV 
infection, poverty, and unemployment [4, 23, 24].
Study Population
Individuals included in this sub-study were origi-
nally enrolled in the HPTN 068 study conducted in the 
Agincourt HDSS [22]. Details of the HPTN 068 trial 
are listed elsewhere [22, 25], but briefly, 2533 young 
women were enrolled. At baseline, participants were ages 
13–20 years, enrolled in grades 8–11, were not married 
or pregnant, were able to complete a computer survey on 
their own, and could open a post office or bank account. 
Participants were randomized to either a cash transfer 
intervention conditional on school attendance, or a control 
group. These AGYW were followed annually and inter-
viewed to assess factors such as socio-economic factors, 
sexual behaviors, mental health, intimate partner violence, 
and alcohol and drug use. AGYW were also tested for HIV 
and herpes simplex virus type 2 (HSV-2) at baseline and 
at each annual study visit until they were considered lost 
to follow-up or matriculated from secondary school and 
formally exited the trial a maximum of three years follow-
ing enrollment into the trial [22].
Individuals testing HIV positive at the baseline HPTN 
068 trial visit were invited to complete a separate follow-
up visit for the Engage sub-study approximately 12 to 
18 months after their initial enrollment in the HPTN 068 
trial. Individuals testing newly HIV positive throughout 
the main HPTN 068 trial were invited to complete a sepa-
rate follow-up visit for the Engage sub-study after their 
initial diagnosis during the trial. This analysis utilizes 
Engage data collected between March 2015 and July 2017 
from all individuals diagnosed with incident HIV through-
out the main trial. Individuals who tested HIV positive at 
trial baseline were excluded, as it was difficult to ascer-
tain a reliable measure of time since HIV diagnosis, a key 
covariate of interest in this sub-study.
Data Collection and Measures
For all Engage study visits, locally hired and trained 
HPTN 068 HIV counselors administered a paper-based 
questionnaire in the participant’s preferred language (Eng-
lish or Xitsonga, the predominant local language).
Self-reported current ART use was the primary out-
come of interest. Current ART use was dichotomized as 
“currently taking any daily treatment for HIV” or no cur-
rent daily treatment for HIV. Specific exposures of inter-
est included social support, HIV-related stigma, and prior 
disclosure of HIV status.
Social support was captured in multiple ways. Partici-
pants were first asked to identify how many individuals 
in their life they felt at ease with and then completed an 
abbreviated 12-item version of the Medical Outcomes 
Study social support scale (MOS-SSS), which captures 
emotional and informational support, tangible support, 
affectionate support, and positive social interaction [26, 
27]. A composite score was obtained by summing the 
responses to all 12 scale items. A minimum score of 12 
represents rare to no support, and a maximum score of 
36 represents support most or all of the time. Each of the 
four sub-scales are comprised of three items and have a 
minimum score of three and a maximum score of nine.
Perceived stigma was measured using the 40-item Berger 
HIV Stigma Scale [28, 29]. The minimum composite stigma 
score of 40 represents the lowest degree of perceived stigma. 
The maximum score of 160 represents the highest degree of 
perceived stigma. This scale is comprised of four subscales 
which measure personalized or enacted stigma (18 items; 
score range: 18 to 72), disclosure concerns (10 items; score 
range: 10 to 40), negative self-image (13 items; score range: 
13 to 52), and concern with public attitudes about people 
with HIV (20 items; score range: 20 to 80).
Self-reported HIV status disclosure to at least one person 
was dichotomized as yes or no. Information was also col-
lected on who participants disclosed their status to and these 
individuals’ reactions following the disclosure.
Other variables of interest included time since HIV diag-
nosis (calculated as the time in years between the individu-
al’s date of diagnosis in the main HPTN 068 trial and date 
of Engage interview), age at Engage interview, self-reported 
care-seeking behaviors, and self-reported experiences with 
the healthcare system. Specifically, AGYW were asked if 
they had previously sought HIV-related medical care since 
their diagnosis and if they had ever taken treatment for 
HIV. AGYW that had previously sought HIV-related care 
were asked to respond to a series of questions about what 
motivated them to seek HIV care, how they were treated by 
medical staff during their last HIV-related medical visit, how 
they got to the clinic, how long it took to get to the clinic, 
and how long they waited for clinic services. Individuals 
who reported they had never sought HIV-related care were 
instead asked why they had not previously sought care for 
HIV.
Ethical Considerations
Written informed consent was obtained from all participants 
ages 18 and older, and written parental consent and assent 
were obtained for any participant under the age of 18. Ethi-
cal approval for this study was obtained from the University 
of North Carolina at Chapel Hill Institutional Review Board, 
the University of the Witwatersrand Human Research Ethics 
Committee, and the Mpumalanga Province Health Research 
Committee.
Analysis
In this analysis we describe general care and support seek-
ing behaviors following HIV diagnosis. For individuals 
who self-reported previously seeking HIV-related care, we 
describe their motivations for seeking care and experiences 
with the local healthcare system at their last medical visit. 
For individuals who self-reported no prior HIV-related care-
seeking, we describe self-reported barriers to care.
Internal consistency and reliability of the modified MOS-
SSS and Berger HIV Stigma scale was assessed using Cron-
bach’s alpha. Alpha values > 0.70 were considered accept-
able. To determine the crude and adjusted associations 
between current ART use and each exposure of interest, log 
binomial regression was used to calculate prevalence ratios 
and the corresponding 95% confidence intervals. Adjusted 
analyses controlled for age and time since HIV diagnosis, 
the a priori determined covariates of interest based on a lit-
erature review of factors influencing ART use and retention 
in HIV care [30–33]. All analyses were conducted using 
SAS Studio 3.8 (SAS Institute, Cary, NC).
Results
Of the 2,533 AGYW enrolled in HPTN 068, 81 tested HIV-
positive at baseline and 107 incident cases were identified 
throughout the trial. Of these 188 AGYW living with HIV, 
143 (76.1%) consented to participate in Engage and were 
subsequently interviewed. Eighty AGYW who participated 
in Engage (55.9%) were incident cases in the main trial, 
and therefore eligible for inclusion in this sub-study. One 
individual was excluded due to missing data on current 
ART use, yielding a sub-study sample size of 79. Partici-
pant ages at time of Engage interview ranged from 17 to 25 
(median = 20) and the median time since initial HIV diagno-
sis was 2.1 years (range: 0.51 to 4.78) (Table 1).
Care‑Seeking
Over 75% of AGYW (n = 60) had sought HIV care at some 
point since diagnosis, yet just 43% (n = 34) were on treat-
ment at the time of the Engage interview. Among those who 
had previously sought care (n = 60), the three most com-
monly reported reasons for visiting the clinic were because 
the AGYW was told to at a main trial study visit (75.0%), 
they did not want to fall ill (66.7%), and they wanted to 
get medicine for HIV (65.0%) (Table 2). The one factor the 
majority of these 60 AGYW (n = 22; 36.7%) reported was 
most helpful during their care-seeking experience was fam-
ily support for seeking care.
Most individuals who sought care took public transpor-
tation to the clinic (n = 30; 50%), and median travel time 
was 30 min (range: 5–90). Thirty-two individuals (53.3%) 
reported waiting more than one hour for services, and 26 
(43.3%) felt staff members did not spend sufficient time with 
them. Fifty-seven AGYW (95.0%) reported feeling better 
after their most recent medical visit because of their experi-
ence with clinic staff. However, three participants (5.0%) 
would not recommend the facility they attended to some-
one else living with HIV, with all three individuals citing 
unfriendly clinic staff as their reason for this response.
Of the 19 individuals who had not previously sought care, 
two individuals did not report barriers to care, 10 (58.8%) 
stated that their belief that they did not have HIV was some-
what important in influencing their decision to postpone 
care, and nine individuals (52.9%) stated they did not feel 
sick or did not think seeking care would help (Table 3).
Disclosure
Sixty AGYW (75.9%) had disclosed their HIV status to at 
least one individual since they were diagnosed at a trial visit, 
and most (n=35; 58.3%) eported they had disclosed to more 
than one person. Most commonly, individuals had disclosed 
their status to their mother (n = 35; 58.3%) and their boy-
friend (n = 35; 58.3%), with 28 (46.7%) of the 60 AGYW 
who disclosed reporting they disclosed to their mother first.
The primary reactions AGYW reported receiving after 
disclosing their status included positive reactions like 
comforting the AGYW (n = 49; 81.7%) and suggesting the 
AGYW see a doctor (n = 52; 86.7%). Negative reactions to 
study participants’ disclosure included being sad (n = 26; 
43.4%), becoming angry (n = 10; 16.7%), forcing AGYW to 
leave their house (n = 2; 3.3%), and leaving the room (n = 1; 
1.7%). Twenty-three (38.3%) AGYW who had shared their 
HIV positive status with someone stated the individual they 
disclosed to sought testing following the disclosure. Among 
the 35 young women who reported disclosing to a boyfriend, 
18 (51.4%) reported that the partner tested for HIV as a 
result of disclosure.
Table 1  Characteristics of 79 adolescent girls and young women living in the Agincourt Health and Socio-Demographic Surveillance System 
site in rural Mpumalanga province, South Africa and newly diagnosed with HIV in HPTN 068
Current ART use (n = 34)
N (%) or median (range)
No current ART use (n = 45)
N (%) or median (range)
Total (n = 79)
N (%) or median (range)
Age 20 (17 to 24) 20 (17 to 24) 20 (17 to 24)
Years since diagnosis 2.26 (0.89 to 3.16) 1.98 (0.51 to 4.78) 2.12 (0.51 to 4.78)
Ever sought HIV care
 Yes 34 (100) 26 (57.8) 60 (75.9)
 No 0 (0.0) 19 (42.2) 19 (24.1)
Ever disclosed HIV status
 Yes 31 (91.2) 29 (64.4) 60 (75.9)
 No 3 (8.8) 16 (35.6) 19 (24.1)
Stigma 88 (80 to 113) 92 (83 to 113) 90 (80 to 113)
 Personalized or enacted stigma 37 (30 to 51) 38 (36 to 52) 37 (30 to 52)
 Disclosure concerns 25 (20 to 29) 27 (22 to 31) 26 (20 to 31)
 Negative self-image 29 (26 to 38) 30 (27 to 39) 30 (26 to 39)
 Concern with public attitudes 43 (38 to 57) 44 (36 to 56) 44 (36 to 57)
Social support 36 (14 to 36) 35 (22 to 36) 36 (14 to 36)
 Emotional/information support 9 (3 to 9) 9 (4 to 9) 9 (3 to 9)
 Tangible support 9 (5 to 9) 9 (6 to 9) 9 (5 to 9)
 Affectionate support 9 (3 to 9) 9 (5 to 9) 9 (3 to 9)
 Positive social interaction 9 (3 to 9) 9 (5 to 9) 9 (3 to 9)
Number of people at ease with 2 (1 to 10) 2 (1 to 10) 2 (1 to 10)
Table 2  Self-reported reasons for seeking HIV care services among 
60 adolescent girls and young women newly diagnosed with HIV dur-
ing HPTN 068
Reason for seeking care N (%)
Told to at a study visit in main trial 45 (75.0)
Did not want to fall ill 40 (66.7)
To get medicine for HIV 39 (65.0)
Told to by parent/guardian 20 (33.3)
Heard on the radio/TV that you should seek care if have 
HIV
11 (18.3)
Feeling ill 11 (18.3)
Heard at school that you should seek care if you have 
HIV
7 (11.7)
Friends suggested that you go 2 (3.3)
Among the individuals who had not disclosed their HIV 
status (n = 19), the most commonly reported reason for post-
poning disclosure was being concerned the individual might 
tell others (n = 16; 84.2%). This concern was followed by 
fear of the individual thinking the AGYW is a bad person 
(n = 15; 79.0%) and not wanting to worry the individual 
(n = 15; 79.0%). Fourteen (73.7%) AGYW also reported they 
were concerned the individual might physically hurt them if 
they disclosed their status.
Social Support
Overall reliability of the MOS-SSS was high (Cronbach’s 
α = 0.86), though reliability of the subscale measures varied 
(Cronbach’s α ranging from 0.54 to 0.69). All sub-scales 
were maintained in result reporting as they have been previ-
ously used throughout the country [34, 35].
The median number of individuals AGYW reported feel-
ing at ease with was 2 (range: 1–10). This was the same 
regardless of current ART use. The median composite social 
support score was 36 (range: 14–36), the highest possible 
score on the scale. This indicates that over half of study 
participants (n = 44; 55.7%) felt emotional and informational 
support, tangible support, affectionate support, and positive 
social interaction most or all of the time when needed. There 
was no difference in reported social support by ART status.
Stigma
Overall reliability of the Berger HIV Stigma Scale was 
high (Cronbach’s α = 0.90), though reliability of subscale 
measures varied (Cronbach’s α ranging from 0.59 to 0.90). 
All sub-scales were maintained in result reporting for 
comparative purposes as subscales have been used among 
ALHIV in similar settings [36].
After dropping one outlier with a composite stigma score 
of 53, the median composite stigma score among AGYW in 
this study was 90 (observed range: 80 to 113; possible scale 
score range: 40–160). Among those currently on ART, the 
median stigma score was 88 (range: 80 to 113), while among 
those not on ART, the median score was 92 (range: 83 to 
113), indicating those on ART had a lower perception of 
HIV-related stigma than those not on ART. Median scores 
on each of the four stigma subscales also differed by current 
treatment status, with those not on ART generally reporting 
higher perceived stigma on each of the four stigma subscales 
(Table 1).
Current ART Use
Just 43% (n = 34) of AGYW were on treatment at the time 
of the Engage interview, a median of 2.1 years (range: 0.5 to 
4.8) after their initial diagnosis with HIV. Univariate analy-
sis suggested a statistically significant relationship between: 
(1) prior HIV status disclosure (p = 0.0294), (2) composite
Berger HIV stigma scale score (p = 0.0484), and (3) the dis-
closure concern subscale of the stigma scale (p = 0.0076),
and current ART use (Table 4). After adjusting for age and
time since diagnosis, these relationships were attenuated
slightly, and the composite stigma score was no longer sig-
nificantly associated with current ART use (p = 0.0656).
Prevalence of ART use among AGYW who had previously
Table 3  Self-reported barriers 
to care among 17 out of 19 
adolescent girls and young 
women who had not sought 
HIV care since their diagnosis 
during HPTN 068
a Two individuals that have not sought care are missing data on these responses
Self-reported barriers to care (n = 17)a Somewhat 
important N 
(%)
Do not believe you have HIV 10 (58.8)
Do not feel sick so you think it’s okay to wait for a while 9 (52.9)
Do not think it will help you 9 (52.9)
Too embarrassed to go 6 (35.3)
Worried that the clinic staff will not treat you well 5 (29.4)
Worried someone might find out you have HIV if you go 5 (29.4)
Worried about the side effects of HIV treatment 4 (23.5)
Scared they will tell your family or friends that you have HIV 4 (23.5)
Do not have money to pay for transport 3 (17.6)
Do not know where to go 3 (17.6)
Parent or carer does not want you to go to the clinic 2 (11.8)
Clinic is too far away 1 (5.9)
Feel too sick to go 1 (5.9)
Clinic timings are inconvenient 1 (5.9)
Prefer to go to a traditional healer 0 (0.0)
disclosed their status was 3.19 (95% CI 1.09, 9.32) times 
that of AGYW who had not previously disclosed their status. 
For each one-unit increase in AGYW’s score on the disclo-
sure concern stigma sub-scale, ART use was 0.88 (95% CI 
0.79, 0.98) times as likely, indicating AGYW with greater 
concern about disclosing their status were significantly less 
likely to report current ART use. While no statistically sig-
nificant relationship was observed between the composite 
stigma scale score or the other stigma subscale scores and 
current ART use in adjusted analyses, trends in regression 
results suggest that individuals with higher perceived stigma 
were less likely to report current ART use. No statistically 
significant relationship was observed between the number 
of individuals AGYW feel at ease with, composite social 
support scale score, or the four social support sub-scales and 
current ART use (Table 4).
Discussion
AGYW living with HIV in South Africa face myriad com-
plex barriers to engagement and retention in HIV care. 
Though HIV care initiation in this study was relatively high 
compared to the national estimates, with over 75% of study 
participants reporting they had sought care at some point 
since their diagnosis, treatment utilization remained low 
with just 43% of participants on ART a median of 2.1 years 
after diagnosis. In this study of AGYW living with HIV, 
prior disclosure of an individual’s HIV status and concerns 
around disclosure were the only factors significantly associ-
ated with self-reported current ART use.
A large proportion of AGYW (75.9%) reported prior dis-
closure of their HIV status, which was significantly asso-
ciated with current ART use in the sample. The primary 
reasons for avoiding HIV status disclosure in this analysis 
included fear that the individual to whom they would like 
to disclose their status might tell others or become physi-
cally violent. While violence can be a risk of HIV status 
disclosure, prior research suggests this is uncommon in rela-
tionships with no prior history of violence [37]. One study 
conducted among pregnant and postpartum women enrolled 
in a randomized control trial in Durban, South Africa, found 
no association between HIV diagnosis and incident intimate 
partner violence [37]. This same study saw an elevated risk 
of incident intimate partner violence among those who chose 
not to disclose their HIV status, indicating non-disclosure 
could serve as a marker for unhealthy relationships and sug-
gests those fearing violence following disclosure should seek 
support from someone other than their intimate partner [37]. 
A potential intervention that could improve onward disclo-
sure and is recommended in the South Africa Department 
of Health’s current ART guidelines for adolescents [38], 
involves assisting individuals living with HIV in identify-
ing an individual that would support them in their diagnosis 
and creating a safe environment for disclosure to take place, 
alleviating AGYW’s concerns regarding reactions following 
disclosure [39].
A large majority of the literature on disclosure in ALHIV 
focuses on parental or guardian disclosure of perinatally-
infected adolescents’ status to the adolescent themselves. 
There is minimal literature focusing solely on establishing 
the relationship between adolescents’ disclosure of their own 
HIV status to others and HIV care outcomes [39]. However, 
one study conducted in Harare City, Zimbabwe found that 
the odds of virological failure among ALHIV who had not 
previously disclosed their HIV status was 5.88 times the 
odds of virological failure among those who had previously 
disclosed [40]. While ensuring perinatally infected adoles-
cents know their HIV status remains crucial to improved 
care outcomes, increasing onward disclosure among AGYW 
living with HIV can yield increased support for care seeking 
and has the potential to improve HIV treatment outcomes 
Table 4  Correlates of anti-
retroviral therapy use among 
79 adolescent girls and young 
women newly diagnosed with 
HIV during HPTN 068
a Adjusted for age and time since diagnosis
b Excluding outlier with composite stigma score of 53
uPR (95% CI) p-value aPRa (95% CI) p-value
Prior HIV status disclosure 3.27 (1.13, 9.51) 0.0294 3.19 (1.09, 9.32) 0.0339
Berger HIV stigma  scoreb 0.96 (0.92, 1.00) 0.0484 0.96 (0.92, 1.00) 0.0656
 Personalized or enacted stigma 0.94 (0.87, 1.02) 0.1574 0.94 (0.87, 1.03) 0.1812
 Disclosure concerns 0.86 (0.77, 0.96) 0.0076 0.88 (0.79, 0.98) 0.0236
 Negative self-image 0.93 (0.84, 1.03) 0.1480 0.93 (0.84, 1.03) 0.1774
 Concern with public attitudes 0.96 (0.90, 1.02) 0.1956 0.96 (0.90, 1.03) 0.2210
Social support 1.05 (0.96, 1.15) 0.3155 1.03 (0.95, 1.14) 0.4155
 Emotional/information support 1.08 (0.87, 1.34) 0.4940 1.05 (0.84, 1.32) 0.6744
 Tangible support 1.10 (0.76, 1.60) 0.6238 1.07 (0.74, 1.55) 0.7181
 Affectionate support 1.07 (0.76, 1.50) 0.7019 1.05 (0.75, 1.47) 0.7695
 Positive social interaction 1.13 (0.88, 1.47) 0.3370 1.12 (0.86, 1.45) 0.4151
as seen in this study and others [39–41]. It is crucial for 
disclosure to be viewed as a complex process rather than a 
one-time event, with interventions such as multi-session sup-
port groups showing the most promise for improving onward 
disclosure in adolescents [42–44].
Stigma has also been repeatedly shown to impede access 
to and retention in care in a number of populations living 
with HIV, including AGYW living with HIV [11, 45–48]. 
A systematic review on factors influencing ART adherence 
among ALHIV in sub-Saharan Africa found that stigma was 
the main barrier to ART adherence in the region [49]. In this 
review, AGYW reporting higher perceived stigma were less 
likely to be on ART than those with lower scores. Elevated 
scores on the “disclosure concerns” sub-scale of the Berger 
HIV Stigma Scale was significantly associated with no cur-
rent ART use in this population of AGYW living with HIV, 
corroborating our results that suggest HIV status disclosure 
plays a crucial role in facilitating ART use among AGYW. 
While no statistically significant associations were observed 
between individuals’ composite stigma scale score or the 
additional stigma sub-scales and current ART use, trends in 
adjusted regression results suggest overall perceived stigma 
could be important in influencing current ART use among 
AGYW living with HIV. In future studies, utilization of 
Pantelic et al.’s ALHIV stigma scale, which was psycho-
metrically assessed and validated among ALHIV in South 
Africa specifically [50], could improve reliability of popula-
tion stigma measures.
AGYW in this study reported high levels of social sup-
port overall. Research conducted in similar contexts sug-
gests an association between social support and retention in 
HIV care among adults [51]; however, we did not see that 
association here. Over half of study participants stated they 
had emotional and informational support, tangible support, 
affectionate support, and positive social interactions most 
or all of the time when needed, and all AGYW surveyed 
reported at least one individual they felt at ease with. These 
high levels of support likely contributed to the lack of an 
association observed between social support and ART use 
in this population.
Perceptions of individual’s healthcare seeking experi-
ences among AGYW who had previously sought HIV-
related healthcare were largely positive despite reports of 
clinic wait times exceeding one hour and insufficient time 
spent with providers. Very few participants who had sought 
HIV-related care stated they would not recommend the 
clinic they attended to someone else living with HIV, while 
most individuals reported feeling better after meeting with 
a service provider at their last visit. Positive experiences of 
healthcare seeking may also be linked to ART being pro-
vided for free at all public health facilities in South Africa.
Among individuals who had not previously sought HIV 
care, holding a belief that they were not infected and not 
feeling ill were the most frequently cited reasons for delay-
ing care, a common finding among ALHIV that delay care 
initiation [10]. Concerns about clinic quality of care and 
accessibility appeared to be less important in this context, 
unlike the results from a number of similar studies [52, 53]. 
Together, our data suggest that challenges to healthcare 
service delivery persist in the Agincourt HDSS, but that 
AGYW living with HIV in the area do not consider this the 
most influential factor impacting their care-seeking behavior. 
This is consistent with evidence suggesting linkage to care 
among ALHIV remains the greatest hurdle in improving 
HIV care outcomes, while retention in care over time is less 
problematic after young people are linked [54].
Several key differences between the study population and 
AGYW living with HIV more broadly should be considered 
when interpreting study findings. First, all newly diagnosed 
AGYW enrolled in HPTN 068 were offered active linkage to 
HIV care services through trained study staff at the time of 
their diagnosis. It is well known that active linkage to care 
programs yield higher proportions of individuals initiating 
ART than passive referral processes [55–57], potentially 
contributing to the overall high percentage of AGYW report-
ing they had previously sought HIV-related healthcare ser-
vices. Additionally, all AGYW in the trial were enrolled in 
school at trial baseline. While this may limit generalizability 
of study findings to AGYW attending school, we believe 
this cohort is more representative of the general population 
of AGYW than a clinical cohort or cohort of individuals 
specifically seeking HIV counseling and testing services. 
Finally, individuals in this trial were repeatedly asked about 
their sexual behaviors and were aware of the fact that they 
were being followed each year by a team of HIV researchers. 
This has the potential to increase motivation to link to care at 
the time of diagnosis and increase care-seeking throughout 
the duration of the trial. While it is unlikely that these factors 
would directly influence long-term outcomes such as ART 
utilization at the time of Engage interview, they should be 
considered as upstream factors that could impact individual 
care-seeking behaviors more broadly.
Several study limitations should also be considered when 
interpreting the results of this sub-study. Notably, South 
African ART treatment initiation guidelines were altered 
during the course of data collection for this study. In Sep-
tember 2016, South Africa launched the nation-wide test 
and treat campaign in alignment with recommendations 
from the World Health Organization. This policy recom-
mends immediate ART initiation for all individuals living 
with HIV, regardless of clinical stage or CD4 count [5, 
58]. Prior to this policy change, individuals with a CD4 
count above 500 were ineligible for ART initiation. This 
could potentially contribute to the low levels of observed 
current ART use in the population, as some AGYW were 
interviewed prior to September 2016. This study was also 
limited by the relatively small sample size of AGYW who 
were newly diagnosed with HIV during HPTN 068 (n = 107) 
and subsequently consented to participation in the Engage 
sub-study (n = 81; 75.7%). Further, current ART use may 
have been over-reported due to social desirability bias and 
lack of capacity to validate self-reported outcomes through 
clinical record review.
Future longitudinal studies conducted in the era of Uni-
versal Test and Treat should aim to ascertain current ART 
use through blood drug level testing, and recruit a larger 
number of participants. This will allow investigators to 
explore more comprehensive exposure-outcome pathways 
while simultaneously maintaining sufficient power to detect 
statistically significant associations.
Conclusions
Low levels of HIV treatment use remain a substantial bar-
rier to improved health outcomes among AGYW living with 
HIV in this resource-limited setting in rural South Africa. 
Disclosure of one’s HIV status is recommended by the South 
African Department of Health and can improve ART utiliza-
tion. Disclosure is a process and should therefore be encour-
aged at the time of an individual’s initial diagnosis with HIV 
and at routine care visits following diagnosis. Perceived 
stigma among ALHIV may also impede ART utilization 
and interventions to address HIV-related stigma must per-
sist. It is essential to routinely monitor barriers to treatment 
use among highly vulnerable AGYW living with HIV in an 
effort to improve the long-term health outcomes of these 
individuals and eliminate onward transmission of the virus. 
While treatment outcomes among AGYW living with HIV 
may be improving in the era of Universal Test and Treat, as 
suggested by these study findings, significant progress is still 
needed if we are to meet UNAIDS’ 90-90-90 targets.
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